Protagonist Therapeutics Inc (PTGX) Shares Bought by Spark Investment Management LLC

Spark Investment Management LLC increased its holdings in Protagonist Therapeutics Inc (NASDAQ:PTGX) by 69.3% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 138,300 shares of the company’s stock after purchasing an additional 56,600 shares during the quarter. Spark Investment Management LLC’s holdings in Protagonist Therapeutics were worth $929,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Farallon Capital Management LLC boosted its position in shares of Protagonist Therapeutics by 12.6% in the 1st quarter. Farallon Capital Management LLC now owns 1,013,500 shares of the company’s stock worth $8,706,000 after buying an additional 113,500 shares in the last quarter. BlackRock Inc. boosted its position in shares of Protagonist Therapeutics by 39.0% in the 1st quarter. BlackRock Inc. now owns 687,160 shares of the company’s stock worth $5,904,000 after buying an additional 192,632 shares in the last quarter. BVF Inc. IL boosted its position in shares of Protagonist Therapeutics by 37.9% in the 1st quarter. BVF Inc. IL now owns 405,600 shares of the company’s stock worth $3,484,000 after buying an additional 111,483 shares in the last quarter. Millennium Management LLC boosted its position in shares of Protagonist Therapeutics by 66.4% in the 1st quarter. Millennium Management LLC now owns 320,739 shares of the company’s stock worth $2,755,000 after buying an additional 128,009 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of Protagonist Therapeutics by 303.3% in the 2nd quarter. Acadian Asset Management LLC now owns 233,830 shares of the company’s stock worth $1,572,000 after buying an additional 175,849 shares in the last quarter. Institutional investors and hedge funds own 65.77% of the company’s stock.

Several equities research analysts recently commented on PTGX shares. Barclays lowered shares of Protagonist Therapeutics from an “overweight” rating to an “equal weight” rating and set a $18.00 price objective on the stock. in a research report on Wednesday, June 6th. ValuEngine upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 18th. Zacks Investment Research upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 11th. Finally, Leerink Swann boosted their price objective on shares of Protagonist Therapeutics from $13.00 to $21.00 and gave the stock an “outperform” rating in a research report on Monday, August 6th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $22.00.

Shares of PTGX stock opened at $9.94 on Monday. Protagonist Therapeutics Inc has a twelve month low of $5.50 and a twelve month high of $23.97. The stock has a market capitalization of $210.91 million, a P/E ratio of -4.76 and a beta of 3.18.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Tuesday, August 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.07). Protagonist Therapeutics had a negative net margin of 56.92% and a negative return on equity of 24.16%. The firm had revenue of $11.67 million during the quarter, compared to analyst estimates of $8.55 million. equities analysts expect that Protagonist Therapeutics Inc will post -1 earnings per share for the current fiscal year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.

Recommended Story: Diversification

Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics Inc (NASDAQ:PTGX).

Institutional Ownership by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply